EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice

Andrea Di Lenarda, Nicola Ferri, Massimiliano Lanzafame, Eva Agostina Montuori, Luciano Pacelli

European Cardiology Review · 09.08.2024 · 19

DOI: 10.15420/ecr.2024.04 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 09.08.2024. Verfasst von Andrea Di Lenarda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center, Territory Specialist Department, Azienda Sanitaria Universitaria Giuliano Isontina - ASUGI Trieste, Italy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular disease is associated with progression to severe COVID-19 and patients with the condition are among those in whom early antiviral therapy should be warranted. The combination of nirmatrelvir/ritonavir (Paxlovid®) has been approved for clinical use by the Food and Drug Administration and European Medicines Agency. Because patients with cardiovascular disease are often on polypharmacy, physicians need to be aware of potential drug–drug interactions (DDIs) when treating COVID-19 with nirmatrelvir/ritonavir. Guidance is given for avoiding DDIs, emphasising that preventing and managing potential DDIs with nirmatrelvir/ritonavir requires thorough assessment and knowledge. The present review summarises the clinical pharmacology of nirmatrelvir/ritonavir and provides details on potential DDIs with a focus on daily practice in patients with cardiovascular disease. Particular attention is needed for drugs that are predominantly metabolised by cytochrome P450 3A4, are substrates of P-glycoprotein and have a narrow therapeutic index. Proper management of potential DDIs must balance the benefit of nirmatrelvir/ritonavir to prevent severe disease with the risk of serious adverse events.

Schlagwörter

Stichwörter der Autor:innen

COVID-19Cardiovasculardrug interactionsnirmatrelvirritonavir

Autor:innen und Institutionen

  • Cardiovascular Center, Territory Specialist Department, Azienda Sanitaria Universitaria Giuliano Isontina - ASUGI Trieste, Italy.
  • Department of Medicine, University of Padova Padua, Italy.
  • Veneto Institute of Molecular Medicine (VIMM) Padua, Italy.
  • Medical Department, Infectious Diseases Unit, Santa Chiara Hospital, APSS Trento, Italy.
  • Medical Department, Pfizer Rome, Italy.

Zitieren

APA

Di Lenarda, A., Ferri, N., Lanzafame, M., Montuori, E. A., & Pacelli, L. (2024). Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice. European Cardiology Review, 19. https://doi.org/10.15420/ecr.2024.04

Vancouver

Di Lenarda A, Ferri N, Lanzafame M, Montuori EA, Pacelli L. Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice. European Cardiology Review. 2024;19. doi:10.15420/ecr.2024.04

BibTeX
@article{DiLenarda2024,
  author = {Di Lenarda, Andrea and Ferri, Nicola and Lanzafame, Massimiliano and Montuori, Eva Agostina and Pacelli, Luciano},
  title = {Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice},
  journal = {European Cardiology Review},
  year = {2024},
  volume = {19},
  doi = {10.15420/ecr.2024.04}
}
Kostenlos starten →